Special Issue PRO-Analysis of Clinically Meaningful Change on Patient-Reported Outcomes : Renewed Insights About Covariate Adjustment
Determining clinically meaningful change (CMC) in a patient-reported (PRO) measure is central to its existence in gauging how patients feel and function, especially for evaluating a treatment effect. Anchor-based approaches are recommended to estimate a CMC threshold on a PRO measure. Determination of CMC involves linking changes or differences in the target PRO measure to that in an external (anchor) measure that is easier to interpret than and appreciably associated with the PRO measure. One type of anchor-based approach for CMC is the "mean change method" where the mean change in score of the target PRO measure within a particular anchor transition level (e.g. one-category improvement) is subtracted from the mean change in score of within an adjacent anchor category (e.g. no change category). In the literature, the mean change method has been applied with and without an adjustment for the baseline scores for the PRO of interest. This article provides the analytic rationale and conceptual justification for keeping the analysis unadjusted and not controlling for baseline PRO scores. Two illustrative examples are highlighted. The current research is essentially a variation of Lord's paradox (where whether to adjust for a baseline variable depends on the research question) placed in a new context. Once the adjustment is made, the resulting CMC estimate reflects an artificial case where the anchor transition levels are forced to have the same average baseline PRO score. The unadjusted estimate acknowledges that the anchor transition levels are naturally occurring (not randomized) groups and thus maintains external validity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of biopharmaceutical statistics - (2023) vom: 01. Aug., Seite 1-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cappelleri, Joseph C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 01.08.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/10543406.2023.2237115 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360262562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360262562 | ||
| 003 | DE-627 | ||
| 005 | 20231226082636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10543406.2023.2237115 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360262562 | ||
| 035 | |a (NLM)37526447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cappelleri, Joseph C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Special Issue PRO-Analysis of Clinically Meaningful Change on Patient-Reported Outcomes |b Renewed Insights About Covariate Adjustment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Determining clinically meaningful change (CMC) in a patient-reported (PRO) measure is central to its existence in gauging how patients feel and function, especially for evaluating a treatment effect. Anchor-based approaches are recommended to estimate a CMC threshold on a PRO measure. Determination of CMC involves linking changes or differences in the target PRO measure to that in an external (anchor) measure that is easier to interpret than and appreciably associated with the PRO measure. One type of anchor-based approach for CMC is the "mean change method" where the mean change in score of the target PRO measure within a particular anchor transition level (e.g. one-category improvement) is subtracted from the mean change in score of within an adjacent anchor category (e.g. no change category). In the literature, the mean change method has been applied with and without an adjustment for the baseline scores for the PRO of interest. This article provides the analytic rationale and conceptual justification for keeping the analysis unadjusted and not controlling for baseline PRO scores. Two illustrative examples are highlighted. The current research is essentially a variation of Lord's paradox (where whether to adjust for a baseline variable depends on the research question) placed in a new context. Once the adjustment is made, the resulting CMC estimate reflects an artificial case where the anchor transition levels are forced to have the same average baseline PRO score. The unadjusted estimate acknowledges that the anchor transition levels are naturally occurring (not randomized) groups and thus maintains external validity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a analysis of covariance | |
| 650 | 4 | |a change scores | |
| 650 | 4 | |a clinical important change | |
| 650 | 4 | |a clinical outcome assessments | |
| 650 | 4 | |a covariate adjustment | |
| 650 | 4 | |a longitudinal analysis | |
| 650 | 4 | |a mean change method | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a within-patient change | |
| 700 | 1 | |a Cislo, Paul R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biopharmaceutical statistics |d 1991 |g (2023) vom: 01. Aug., Seite 1-14 |w (DE-627)NLM012811432 |x 1520-5711 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:08 |g pages:1-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10543406.2023.2237115 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 08 |h 1-14 | ||